Corporate News     03-Jul-24
Alembic Pharmaceuticals receives USFDA approval (final & tentative) for 11 products

Alembic Pharmaceuticals has received 11 US Food & Drug Administration (USFDA) Product Approvals (Final & Tentative) during the quarter ended 30 June 2024. The products and indication is summarized as under:

Clindamycin Phosphate Topical Gel USP 1% Clindamycin phosphate gel is indicated in the treatment of acne vulgaris.
Diazepam Injection USP, 10mg/2mL (5 mg/mL), Single-Dose Prefilled Syringe Diazepam Injection USP Diazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. 
Selexipag Tablets 1,000mcg and 1,200mcg. Selexipag tablets are indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Binimetinib Tablets 15mg Binimetinib tablet is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Tretinoin Cream USP, 0.1%, Tretinoin Cream is indicated for topical application in the treatment of acne vulgaris.
Sacubitril and Valsartan Tablets, 24mg/26mg, 49mg/51mg, and 97mg/103 mg. Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. It is also indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in paediatric patients aged one year and older.
Methotrexate Tablets USP, 2.5mg Methotrexate Tablets are indicated for the treatment of neoplastic diseases, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriasis.
Venlafaxine Hydrochloride Extended-Release Capsules USP, 37.5mg, 75mg, and 150mg. Venlafaxine Hydrochloride Extended-Release Capsules are indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder.
Icatibant Injection, 30mg/3 mL (10 mg/mL) Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Dabigatran Etexilate Capsules, 75mg and 150mg Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients; treatment and reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients.
Dabigatran Etexilate Capsules, 110mg Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients; treatment and reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients
Doxycycline Capsules, 40mg. Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Bosutinib Tablets, 100mg and 500mg Bosutinib tablets are indicated for the treatment of adult patients with a certain type of leukemia called Philadelphia chromosomepositive chronic myelogenous leukemia. 
Previous News
  Alembic Pharmaceuticals reports consolidated net profit of Rs 120.60 crore in the June 2023 quarter
 ( Results - Announcements 04-Aug-23   14:15 )
  Alembic Pharma jumps on USFDA nod for glaucoma drug
 ( Hot Pursuit - 31-Mar-23   10:10 )
  Alembic Pharma gets USFDA nod for hypertension drug
 ( Hot Pursuit - 30-Mar-23   14:08 )
  Alembic Pharmaceuticals reports consolidated net loss of Rs 65.88 crore in the June 2022 quarter
 ( Results - Announcements 04-Aug-22   17:27 )
  Alembic Pharmaceuticals to conduct AGM
 ( Corporate News - 20-Sep-22   16:05 )
  Alembic Pharma receives PAS approval for its sANDA Pregabalin Capsules
 ( Corporate News - 22-Dec-22   13:53 )
  Alembic Pharmaceuticals receives USFDA approval for Diclofenac Sodium Topical Gel, 3%
 ( Corporate News - 29-Jul-22   10:43 )
  Alembic Pharma records 48% growth in Q3 PAT
 ( Hot Pursuit - 05-Feb-24   16:29 )
  Alembic Pharma gets USFDA final approval for Prazosin Hydrochloride capsules
 ( Hot Pursuit - 08-Mar-23   09:19 )
  Alembic Pharmaceuticals' subsidiary gets USFDA approval
 ( Hot Pursuit - 12-Apr-22   10:55 )
  Alembic Pharmaceuticals to hold board meeting
 ( Corporate News - 28-Jan-22   17:38 )
Other Stories
  Share India Securities allots 16.92 lakh equity shares on conversion of warrants
  06-Jul-24   13:11
  Tinna Trade raises Rs 49 cr to fund its growth plans
  06-Jul-24   11:10
  Integra Essentia announces merger with G G Engineering
  06-Jul-24   11:05
  Ugro Capital to raise Rs 75 cr via NCD issuance
  06-Jul-24   10:58
  Board of D.P. Abhushan approves preferential allotment of shares and warrants
  06-Jul-24   10:50
  Life Insurance Corporation of India invest Rs 14 cr in Sri Lankan subsidiary
  06-Jul-24   10:49
  High Energy Batteries (India) to discuss results
  06-Jul-24   10:29
  Havells India schedules board meeting
  06-Jul-24   10:29
  Axis Bank announces board meeting date
  06-Jul-24   10:29
  Mastek to conduct board meeting
  06-Jul-24   10:29
Back Top